BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2816118
Number of visits today
238
Number of downloads
2065786
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, Pabst T. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers 2022;14:2516. [DOI: 10.3390/cancers14102516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, Hoffmann M, Daskalakis M, Akhoundova D, Pabst T. CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma. IJMS 2023;24:5688. [DOI: 10.3390/ijms24065688] [Reference Citation Analysis]
2 Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, Bacher U, Pabst T. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. Biomolecules 2023;13. [PMID: 36830750 DOI: 10.3390/biom13020382] [Reference Citation Analysis]
3 Del Toro-Mijares R, Oluwole O, Jayani RV, Kassim AA, Savani BN, Dholaria B. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options. Br J Haematol 2023. [PMID: 36709623 DOI: 10.1111/bjh.18656] [Reference Citation Analysis]
4 Heini AD, Bacher U, Porret N, Wiedemann G, Legros M, Stalder Zeerleder D, Seipel K, Novak U, Daskalakis M, Pabst T. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells 2022;11:2747. [PMID: 36078155 DOI: 10.3390/cells11172747] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345